Key Developments: Medigen Biotechnology Corp (3176.TWO)

3176.TWO on Gre Tai Securities Market of Chinese Taipei

133.00TWD
1:30am EDT
Change (% chg)

NT$-6.50 (-4.66%)
Prev Close
NT$139.50
Open
NT$137.50
Day's High
NT$138.50
Day's Low
NT$132.00
Volume
1,270
Avg. Vol
1,022
52-wk High
NT$486.00
52-wk Low
NT$105.50

Search Stocks

Latest Key Developments (Source: Significant Developments)

Medigen Biotechnology announces no dividend payment for 2014
Wednesday, 25 Mar 2015 05:46am EDT 

Medigen Biotechnology Corp:To pay no dividend to shareholders for 2014.  Full Article

Medigen Biotechnology Corp announces positive trial result
Tuesday, 8 Jul 2014 03:40am EDT 

Medigen Biotechnology Corp:Announces positive trial result of stage three for PI-88.PI-88 is a new drug for liver cancer.  Full Article

Medigen Biotechnology subsidiary signs license contract
Friday, 25 Apr 2014 04:58am EDT 

Medigen Biotechnology Corp:Says vaccine subsidiary signed license contract to obtain authorization of H7N9 influenza vaccine technologies from National Health Research Institutes.  Full Article

Medigen Biotechnology Corp announces no dividend for FY 2013
Monday, 17 Mar 2014 07:06am EDT 

Medigen Biotechnology Corp:Announces no dividend payment for fiscal year 2013.  Full Article

Medigen Biotechnology Corp appoints CEO
Monday, 17 Mar 2014 07:01am EDT 

Medigen Biotechnology Corp:Appoints Zhang Shizhong, the company's chairman of the board, as new chief executive officer, effective March 17.  Full Article

Medigen Biotechnology Corp announces phase III PI-88 clinical trial result
Sunday, 29 Dec 2013 06:42pm EST 

Medigen Biotechnology Corp:Says obtained positive result for the phase III clinical trial of PI-88, a early treatment drug of liver cancer.  Full Article

Medigen Biotechnology Corp obtains patent
Wednesday, 18 Dec 2013 07:36pm EST 

Medigen Biotechnology Corp:Says the company has received a patent for its liver cancer drug OBP-301 from European Patent Office (EPO).Says OBP-301, which is a kind of oncolytic virotherapy drug, has received patents in the United States, Japan, China and South Korea.Says the company will initiate clinical trial for OBP-301 in the first half of 2014.  Full Article

Medigen Biotechnology Corp Announces Updates on Acquisition of Stake in Winston Medical Supply Co., Ltd through Stock Swap
Sunday, 10 Nov 2013 07:48pm EST 

Medigen Biotechnology Corp announced that it will acquire a 67.92% stake in Winston Medical Supply Co., Ltd through stock swap. The Company will issue 2,000,000 new shares to acquire the stake in Winston Medical Supply Co., Ltd. Nine shares of Winston Medical's common stock can be exchanged into one share of the Company's common stock. After the transaction, Winston Medical will become a subsidiary of the Company in January 2014.  Full Article

Medigen Biotechnology Corp to Acquire Stake in Winston Medical Supply Co., Ltd through Stock Swap
Friday, 8 Nov 2013 03:47am EST 

Medigen Biotechnology Corp announced that it will acquire stake in Winston Medical Supply Co., Ltd through stock swap. Nine share of Winston Medical's common stock will be exchanged into one share of the Company's common stock. Winston Medical will become a subsidiary of the Company, on January 10, 2014.  Full Article

Medigen Biotechnology Corp Completes Share Issuance
Friday, 4 Oct 2013 12:13am EDT 

Medigen Biotechnology Corp announced that it has completed its issuance of 8 million common shares at a price of NTD 150 per share, and raised NTD 1.2 billion as of October 4, 2013.  Full Article

Search Stocks